Transparency and Trust

Promoting the needs and rights of patients, employees and society at large is vital to us at Ipsen and it is exactly the objective and essence of our Corporate Social Responsibility Strategy.   Our vision is to harness the power of our employees to have a responsible and sustainable impact on patients, society and the environment.  We need to act with integrity, meaning that we must build relationships based on trust. 

Transparency is also vital to building trust with patients, policy-makers, healthcare professionals (HCPs), healthcare organizations (HCOs) and citizens.  We are committed to meeting the growing and legitimate expectations of healthcare companies in society. This is why we seek to enhance understanding about the way our sector operates.

We conform to the highest ethical standards, in compliance with the ruling laws, regulations and industry codes.  As such, we disclose information concerning:

  • The transfer of values to HCPs/HCOs
  • Clinical trials
  • Scientific publications
  • Interactions with policy-makers
  • Support to Patient Organizations

Ipsen is committed to build sustainable and transparent partnerships with patient advocacy groups, medical societies, trade associations and policy-makers.


Interest representation activities

As part of our interest representation activities, Ipsen regularly exchange views with representatives of the organized civil society (patient advocacy groups, medical and scientific organisations) trade associations and policy-makers.

Ipsen is committed to promoting evidence-based discussions between all stakeholders on policies concerning the management of conditions on which we focus.


Applicable laws, policies and industry codes

Interest representation activities are governed by specific local, regional and international codes and guidelines.

The European Parliament and European Commission acquired a European Transparency Register and a Transparency Code of Conduct. Designed for all individuals engaged in EU policy making and policy implementation, these tools set the framework for transparent interactions between interest representatives and EU institutions’ staff members. Registration preconditions accreditations to the EU institutions.

In the United States, Congress has passed the Lobbying Disclosure Act (LDA). This legislation aimed to bring a level of accountability to federal lobbying practices. Federal lobbyists are now required to register with the Clerk of the United States House of Representatives and the Secretary of the United States Senate. Also, monies used to directly or indirectly support lobbying activties, including retention of paid consultants, must be disclosed.

In addition, local, regional and global trade associations representing the R&D-based pharmaceutical industry issued several codes and guidance related to interest representation:

  • Pharmaceutical Research and Manufacturers of America (PhRMA) and European Federation of Pharmaceutical Industries and Associations (EFPIA) respectively published “Principles on Interactions with Patient Organisations” and a “Code of Practice on Relationships between the Pharmaceutical Industry and Patient Organisations”.
  • EFPIA’s guidance to the “EU Transparency Register”.
  • The International Federation of Pharmaceutical Manufacturers & Associations’ (IFPMA) “Code of Practice”.
  • PhRMA Code on Interactions With Health Care Professionals


Ipsen’s commitment

Ipsen is registered to the European Transparency Register on which are disclosed

  • detailed information about our business activities,
  • the names of all interest representatives working for Ipsen and accredited by the EU institutions to access the European Parliament premises,
  • the costs incurred annually for interest representation activities covered by the scope of the Register.

In addition, Ipsen operates in full compliance with the local, regional and global trade associations’ codes and guidance designed in regard to transparency on interest representation activities as listed above.